Chief Financial Officer
Michael Faerm has more than 20 years of life sciences, equity research, and investment banking experience. He was most recently a consulting and interim Chief Financial Officer and Chief Business Officer for numerous biopharma companies, at MEF Consulting LLC and Burkland Associates. Mike’s Wall Street experience includes Credit Suisse and Wells Fargo Securities, where he was a senior equity research analyst covering the pharmaceutical sector, and Merrill Lynch, where he was an investment banker executing a wide range of strategic and capital markets transactions in biopharma and other healthcare sectors. Mike’s operating experience includes serving as the Chief Business Officer of Innoviva, Inc. (formerly Theravance, Inc.), where he led corporate development activities and advised on investor relations and finance strategy. He also worked in business development at Forest Laboratories, sourcing and executing deals with growing biotech companies, and at Regeneron Pharmaceuticals, where he led long-term financial planning and helped execute a collaboration agreement for Eylea®, one of the top drugs by global sales. Mike earned his MBA from Harvard Business School, a M.S. in civil engineering from Stanford University, and a B.S. in civil engineering from Columbia University.